Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy.

Gomes A, Reyes EV, Garduno LS, Rojas R, Mir Mesejo G, Del Rosario E, Jose L, Javier C, Vaughan C, Donastorg Y, Hammer S, Brudney K, Taylor BS.

PLoS One. 2016 Aug 10;11(8):e0160797. doi: 10.1371/journal.pone.0160797. eCollection 2016.

2.

Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.

Rokx C, Richman DD, Müller-Trutwin M, Silvestri G, Lunzen J, Khoo S, Lichterfeld M, Altfeld M, Perno CF, Hunt PW, Mallon P, Rockstroh JK, Pozniak AL, Clotet B, Boucher CA.

J Virus Erad. 2015 Jul 1;1(3):211-20.

3.

Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions.

Serrano-Villar S, Gutiérrez F, Miralles C, Berenguer J, Rivero A, Martínez E, Moreno S.

Open Forum Infect Dis. 2016 May 12;3(2):ofw097. doi: 10.1093/ofid/ofw097. eCollection 2016 Apr. Review.

4.

Cardiovascular disease risk scores' relationship to subclinical cardiovascular disease among HIV-infected and HIV-uninfected men.

Monroe AK, Haberlen SA, Post WS, Palella FJ Jr, Kinsgley LA, Witt MD, Budoff M, Jacobson LP, Brown TT.

AIDS. 2016 Aug 24;30(13):2075-84. doi: 10.1097/QAD.0000000000001163.

PMID:
27203714
5.

Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study.

Quiros-Roldan E, Raffetti E, Donato F, Magoni M, Pezzoli C, Ferraresi A, Brianese N, Castelnuovo F, Focà E, Castelli F.

PLoS One. 2016 May 5;11(5):e0154900. doi: 10.1371/journal.pone.0154900. eCollection 2016.

6.

Transforming growth factor-β1-mediated cardiac fibrosis: potential role in HIV and HIV/antiretroviral therapy-linked cardiovascular disease.

Ahamed J, Terry H, Choi ME, Laurence J.

AIDS. 2016 Feb 20;30(4):535-42. doi: 10.1097/QAD.0000000000000982. No abstract available.

PMID:
26605511
7.

Cardiovascular health knowledge and preventive practices in people living with HIV in Kenya.

Temu TM, Kirui N, Wanjalla C, Ndungu AM, Kamano JH, Inui TS, Bloomfield GS.

BMC Infect Dis. 2015 Oct 14;15:421. doi: 10.1186/s12879-015-1157-8.

8.

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.

Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G.

Lipids Health Dis. 2015 Jun 19;14:57. doi: 10.1186/s12944-015-0054-x.

9.

HIV and coronary artery calcium score: comparison of the Hawaii Aging with HIV Cardiovascular Study and Multi-Ethnic Study of Atherosclerosis (MESA) cohorts.

Chow D, Young R, Valcour N, Kronmal RA, Lum CJ, Parikh NI, Tracy RP, Budoff M, Shikuma CM.

HIV Clin Trials. 2015 Aug;16(4):130-8. doi: 10.1179/1528433614Z.0000000016. Epub 2015 Jun 3.

10.

Epidemiology and management of antiretroviral-associated cardiovascular disease.

Chastain DB, Henderson H, Stover KR.

Open AIDS J. 2015 Mar 31;9:23-37. doi: 10.2174/1874613601509010023. eCollection 2015.

11.

Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons.

Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng CH, Currier JS, Butt AA; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study.

AIDS Res Hum Retroviruses. 2015 Jul;31(7):718-22. doi: 10.1089/AID.2014.0284. Epub 2015 May 11.

12.
13.

Traditional risk factors are more relevant than HIV-specific ones for carotid intima-media thickness (cIMT) in a Brazilian cohort of HIV-infected patients.

Pacheco AG, Grinsztejn B, da Fonseca Mde J, Moreira RI, Veloso VG, Friedman RK, Santini-Oliveira M, Cardoso SW, Falcão M, Mill JG, Bensenor I, Lotufo P, Chor D.

PLoS One. 2015 Feb 18;10(2):e0117461. doi: 10.1371/journal.pone.0117461. eCollection 2015.

14.

Cardiovascular Complications of HIV-Associated Immune Dysfunction.

Zaaqoq AM, Khasawneh FA, Smalligan RD.

Cardiol Res Pract. 2015;2015:302638. doi: 10.1155/2015/302638. Epub 2015 Jan 11. Review.

15.

Metabolic syndrome, diabetes, and cardiovascular risk in HIV.

Nix LM, Tien PC.

Curr HIV/AIDS Rep. 2014 Sep;11(3):271-8. doi: 10.1007/s11904-014-0219-7. Review.

16.

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

Hulgan T, Boger MS, Liao DH, McComsey GA, Wanke CA, Mangili A, Walmsley SL, McCreath H, Milne GL, Sanchez SC, Currier JS, Lake JE.

Mediators Inflamm. 2014;2014:803095. doi: 10.1155/2014/803095. Epub 2014 Jun 1.

17.

Cardiovascular disease risk in an aging HIV population: not just a question of biology.

So-Armah K, Freiberg MS.

Curr Opin HIV AIDS. 2014 Jul;9(4):346-54. doi: 10.1097/COH.0000000000000065. Review.

18.

Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Ross Eckard A, Longenecker CT, Jiang Y, Debanne SM, Labbato D, Storer N, McComsey GA.

HIV Med. 2014 Oct;15(9):537-46. doi: 10.1111/hiv.12143. Epub 2014 Mar 20.

19.

Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, García Morillo JS, Egido J, Noval ML, Ferrando-Martinez S, Blanco-Colio LM, Genebat M, Villar JR, Moreno-Luna R, Moreno JA.

PLoS One. 2014 Mar 4;9(3):e90541. doi: 10.1371/journal.pone.0090541. eCollection 2014.

20.

Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study.

Dawood FZ, Roediger MP, Grandits G, Miller D, Fisher M, Zhang ZM, Hodder S, Hoy JF, Lundgren JD, Neaton JD, Soliman EZ; INSIGHT SMART Study Group.

J Electrocardiol. 2014 Mar-Apr;47(2):264-71. doi: 10.1016/j.jelectrocard.2013.12.001. Epub 2013 Dec 4.

Items per page

Supplemental Content

Write to the Help Desk